UnknownPhase 2NCT05288478
Dose-ranging Study of Dentoxol® Mouthrinse for Managing Oral Symptoms in People With Epidermolysis Bullosa.
Studying Inherited epidermolysis bullosa
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Chile
- Principal Investigator
- Susanne Kramer, MsCUniversity of Chile
- Intervention
- Dentoxol mouthrinse dosages(combination_product)
- Enrollment
- 100 target
- Eligibility
- 6 years · All sexes
- Timeline
- 2022 – 2023
Study locations (1)
- Facultad de Odontología, Universidad de Chile, Santiago, Santiago Metropolitan, Chile
Collaborators
Fundación DEBRA Chile, Niños Piel de Cristal
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05288478 on ClinicalTrials.govOther trials for Inherited epidermolysis bullosa
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT05838092Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)RHEACELL GmbH & Co. KG
- ACTIVE NOT RECRUITINGPHASE3NCT05464381Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)RHEACELL GmbH & Co. KG
- ACTIVE NOT RECRUITINGNANCT05248503Impact of Complex Care Training of Hereditary Epidermolysis Bullosa on Caregiver Burden (FIREB)Assistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT05954416FARD (RaDiCo Cohort) (RaDiCo-FARD)Institut National de la Santé Et de la Recherche Médicale, France